BiotechTube
Home/Alumis/Roy Hardiman
RH

Roy Hardiman

Chief Business and Strategy Officer

Alumis

Therapeutic Areas

ImmunologyDermatologyAutoimmune Diseases

Alumis Pipeline

DrugIndicationPhase
Envudeucitinib (ESK-001)Moderate-to-Severe Plaque PsoriasisPhase 3
EnvudeucitinibModerate-to-Severe Systemic Lupus ErythematosusPhase 2
A-005Undisclosed Immune-Mediated DiseaseDiscovery/Preclinical

Leadership Team at Alumis

MB
Martin Babler
President, Chief Executive Officer and Chairman of the Board
MB
Mark Bradley
Chief Development Officer
KB
Kolbot By
SVP, Head of Technical Operations
JD
Jack Danilkowicz
Chief Commercial Officer
JD
Jörn Drappa
Chief Medical Officer
DM
David M Goldstein
Chief Scientific Officer
GH
Grace Halteh
SVP, Head of Quality and Regulatory
CL
Claire Langrish
SVP, Head of Immunology and Translational Science
SP
Sanam Pangali
Chief Legal Officer and Corporate Secretary
JS
John Schroer
Chief Financial Officer
View full Alumis profile